Financials data is unavailable for this security.
View more
Year on year Amicus Therapeutics Inc grew revenues 32.29% from 399.36m to 528.30m while net income improved from a loss of 151.58m to a smaller loss of 56.11m.
| Gross margin | 89.77% |
|---|---|
| Net profit margin | -2.35% |
| Operating margin | 5.48% |
| Return on assets | -1.70% |
|---|---|
| Return on equity | -6.87% |
| Return on investment | -2.17% |
More ▼
Cash flow in USDView more
In 2024, cash reserves at Amicus Therapeutics Inc fell by 33.36m. Cash Flow from Financing totalled 5.12m or 0.97% of revenues. In addition the company used 33.89m for operations while cash used for investing totalled 560.00k.
| Cash flow per share | -0.021 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.7469 |
|---|---|
| Tangible book value per share | 0.058 |
More ▼
Balance sheet in USDView more
| Current ratio | 2.99 |
|---|---|
| Quick ratio | 2.09 |
| Total debt/total equity | 1.70 |
|---|---|
| Total debt/total capital | 0.6298 |
More ▼
